Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Peter Ellis, MD, MPH and Lydia S. Dugdale, MD, MAR
Presenting all, including expensive, options to all patients means advocating not only for individual patients, but also for a just health care system.
AMA J Ethics. 2019;21(1):E26-31. doi:
10.1001/amajethics.2019.26.
Martin Bricknell, PhD, David Whetham, PhD, Richard Sullivan, PhD, and Peter Mahoney, PhD
International humanitarian law obliges clinicians to coordinate with local civilian, military, and nongovernment organizations, and implementation isn't easy.
AMA J Ethics. 2022;24(6):E472-477. doi:
10.1001/amajethics.2022.472.